Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc.

The SPDR S&P 500 ETF Trust ($SPY) is up 0.29% in the pre-market trading session on Tuesday, primarily driven by optimism surrounding a major U.S.–I...

SPY ETF Daily Update, 2/3/2026

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna’s latest clinical update centers on a long‑term extension of its cytom...

Moderna’s CMV Vaccine Extension Study Reaches Completion, Setting the Stage for Next Growth Catalyst

Memory chip stocks soared while software sank during the month. 


SNDK, MU, CRM: January’s Best and Worst-Performing Stocks

Moderna ( ($MRNA) ) has fallen by -8.17%. Read on to learn why. Moderna shares fell 8.17% over the past week, even as the company and partner Merck...

Moderna Stock Slips As Ambitious Cancer Trials Drag On

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an announcement. Alterity Therapeutics reported a robust second quarter of FY26, highlighting str...

Alterity Sharpens ATH434 Phase 3 Plans as Phase 2 MSA Data Strengthen

The SPDR S&P 500 ETF Trust ($SPY) is up 0.28% in the pre-market trading session on Wednesday, primarily driven by strong gains in major technology ...

SPY ETF Daily Update, 1/28/2026

The Vanguard S&P 500 ETF (VOO), which tracks the S&P 500 Index (SPX), was up about 0.27% in premarket trading on Tuesday, supported by gains in maj...

Vanguard S&P 500 ETF (VOO) Daily Update, 1/27/2026

Moderna ($MRNA) announced an update on their ongoing clinical study. Merck and Moderna Advance Lung Cancer Vaccine Study With Keytruda Combo Study ...

Moderna and Merck Push Personalized Lung Cancer Vaccine Combo Into Phase 3: What Investors Should Know

Moderna ($MRNA) announced an update on their ongoing clinical study. Study OverviewThis Phase 3 study, officially titled “A Phase 3, Randomized, Do...

Moderna and Merck Advance Phase 3 Cancer Vaccine Combo in Lung Cancer: What Investors Should Know

Moderna ( ($MRNA) ) has risen by 16.45%. Read on to learn why. Moderna’s shares have climbed 16.45% over the past week as investors refocus on the ...

Moderna’s Cancer Bets Ignite Powerful Stock Rebound

In a report released today, Linda Tsai from Jefferies maintained a Hold rating on Moderna, with a price target of $30.00. Tsai covers the Real Esta...

Jefferies Sticks to Their Hold Rating for Moderna (MRNA)

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, is heading down in pre-market trading on Friday. Overall, V...

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/23/26

Berenberg Bank analyst Harry Gillis maintained a Hold rating on Moderna yesterday and set a price target of $32.00. The company’s shares closed yes...

Moderna (MRNA) Receives a Hold from Berenberg Bank

Traders seeking the most recent earnings reports, analyst updates, deals, and other news will find them in the TipRanks daily wrap-up.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

The company’s cash pile has dwindled. 


Moderna Stock (MRNA) Jumps 10% on Positive Results for Cancer Drug

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna (MRNA) is running a long-term extension study for its ...

Moderna Extends Rare Disease Bet With Long-Term mRNA-3705 Study in MMA

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna is running a follow-on clinical trial to track long-te...

Moderna Extends mRNA-3927 Rare Disease Trial, Signaling Long-Term Bet Beyond Vaccines

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna (MRNA) is running a Phase 2 trial called “A Phase 2, R...

Moderna Expands mRNA Pipeline Into Multiple Sclerosis With New Phase 2 Trial

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview Moderna (MRNA) is running a late-stage trial to test a new vacc...

Moderna’s Norovirus Vaccine Trial Advances: What Investors Should Know About mRNA-1403

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview Moderna is running a global early-stage study called “A Global,...

Moderna Advances Rare Disease mRNA Therapy With Ongoing Propionic Acidemia Trial

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna (MRNA) is running a late-stage study titled “A Phase 3...

Moderna’s New Variant-Focused COVID Booster Study: What Investors Should Watch

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview Moderna is running a new early-stage cancer study titled “A Pha...

Moderna Expands Its mRNA Reach With New Multiple Myeloma Trial

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview Moderna (MRNA) is running a Phase 1/2 trial titled “Phase 1/2 S...

Moderna Expands Its Oncology Bet With Ongoing mRNA-4359 Trial in Advanced Solid Tumors

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna (MRNA) is running a Phase 3 study titled “A Phase 3 Op...

Moderna Advances RSV Booster Strategy With New Phase 3 Study in Older Adults

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna is running a long-term Phase 2 extension study titled ...

Moderna’s Long-Term CMV Vaccine Study: What Investors Should Watch Now

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview: Moderna (MRNA) is running an early-stage cancer study titled “...

Moderna Expands Its Cancer Pipeline With New mRNA-4106 Immunotherapy Trial

Moderna ($MRNA) announced an update on their ongoing clinical study. Study Overview Moderna (MRNA) is running a long-term safety study in South Kor...

Moderna Expands Real-World Safety Tracking for Updated SPIKEVAX Vaccines in Korea

Moderna ($MRNA) announced an update on their ongoing clinical study. Study OverviewThis Phase 2 study, officially titled “A Phase 2, Observer-Blind...

Moderna’s CMV Vaccine Trial in Transplant Patients: What Investors Should Watch Now

Alterity Therapeutics ( ($AU:ATH) ) has issued an announcement. Alterity Therapeutics reported that it successfully completed its Phase 2 clinical ...

Alterity Therapeutics Advances Lead MSA Drug Toward Phase 3 After Strong Phase 2 Data

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rapport Therapeutics, Inc. (RAPP – Research Report) and Moderna (...

Analysts Conflicted on These Healthcare Names: Rapport Therapeutics, Inc. (RAPP) and Moderna (MRNA)

The Vanguard S&P 500 ETF ($VOO) is down 0.04% over the past five days but up 14.7% in 2025. Importantly, VOO closely tracks the S&P 500 Index ($SPX...

Vanguard S&P 500 ETF (VOO) Daily Update, 1/19/2026

The SPDR S&P 500 ETF Trust ($SPY) is down 0.04% over the past five days but has gained 1.42% year-to-date. Importantly, SPY closely tracks the S&P ...

SPY ETF Daily Update, 1/19/2026

Moderna ( ($MRNA) ) has risen by 23.61%. Read on to learn why. Moderna’s stock has surged 23.61% over the past week as investors responded to a mix...

Moderna Stock Roars Back on Bold Turnaround Hopes

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna’s latest Phase 4 study, titled “A Phase 4, Randomized, Observer-Blind,...

Moderna Targets Mid-Age Adults With New Variant COVID-19 Booster Study

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics Limited has notified the market of the issue of 43.5 mil...

Alterity Therapeutics Issues 43.5 Million Unlisted Options Under Employee Incentive Scheme

The SPDR S&P 500 ETF Trust ($SPY) was down 0.82% in early trading on Wednesday. The fall appears to be driven by disappointing bank earnings report...

SPY ETF Daily Update, 1/14/2026

Jefferies analyst Linda Tsai maintained a Hold rating on Moderna today and set a price target of $30.00. According to TipRanks, Tsai is a 4-star an...

Moderna (MRNA) Gets a Hold from Jefferies

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics has released a brief corporate communication noting ...

Alterity Flags Risk Context for Forward-Looking Statements in 2026 Presentation

The SPDR S&P 500 ETF Trust ($SPY) is up 0.04% on Monday morning as rising tensions between the Trump administration and the Federal Reserve raised ...

SPY ETF Daily Update, 1/12/2026

Traders will find the latest deals, analyst coverage, and economic data in the Monday wrap-up.


Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

The latest update is out from Moderna ( ($MRNA) ). On January 12, 2026, Moderna reported that it expected unaudited 2025 revenue of about $1.9 bill...

Moderna updates 2025 outlook and highlights pipeline progress

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), R...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (RNAC), Rani Therapeutics Holdings (RANI) and Haemonetics (HAE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cartesian Therapeutics (RNAC – Research Report), Evo...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Evolus (EOLS) and Dexcom (DXCM)

The Vanguard S&P 500 ETF&nbsp;($VOO), which tracks the S&P 500 Index&nbsp;(SPX), is down about 0.18% in pre-market trading today. The move reflects...

Vanguard S&P 500 ETF (VOO) Daily Update, 1/8/2026

In a report released on January 5, Geoff Meacham from Citi maintained a Hold rating on Moderna, with a price target of $28.00. Meacham covers the H...

Citi Keeps Their Hold Rating on Moderna (MRNA)

Citi analyst Geoff Meacham reiterated a Hold rating on Avidity Biosciences on January 5 and set a price target of $72.00. Meacham covers the Health...

Citi Sticks to Its Hold Rating for Avidity Biosciences (RNA)

The Vanguard S&P 500 ETF ($VOO), which tracks the S&P 500 Index (SPX), is up about 0.02% in pre-market trading today. On Tuesday, the ETF rose 0.59...

Vanguard S&P 500 ETF (VOO) Daily Update, 1/7/2026

UBS analysts downgraded Moderna ($MRNA) stock to Hold from Buy and cut its price target to $34 from $40. The firm warned that the biotechnology com...

“Watch Closely” UBS Downgrades Moderna Stock (MRNA) as Profit Outlook Weakens

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has announced the expiry of 91,392,720 unexercised...

Alterity Therapeutics Options Lapse, Removing Potential Dilution Overhang

In a report released today, Yanan Zhu from Wells Fargo maintained a Buy rating on Avidity Biosciences, with a price target of $75.00. Zhu covers th...

Market Cap	$8.98B	P/E Ratio	N/A
52W High	$72.74	52W Low	$21.51
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-0.5%	52W Position	100.0%
Overall Score	61	Value Score	40
Quality Score	60	Technical Score	83

EPS Current Est	$-4.61	EPS Next Est	$-5.21
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$72.74	+0.23%	1.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$72.74	+0.2%	1.40M
3
4
5
6

RNA

RNA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Avidity Biosciences Inc. Data in Excel

Get Avidity Biosciences Inc. Data in Excel